As project manager at AstraZeneca (www.astrazeneca.com) in Lund, Sweden, Orest Lastow is responsible for developing a new dry-powder inhalation platform. The platform includes a new device, a new formulation type and all manufacturing equipment. He has developed and introduced a novel product development methodology for complex projects, called Redundancy Based Development, to address and mitigate development risks and project delays.
Lastow received a M.Sc. in engineering physics and a licentiate of engineering degree in aerosol science from LundUniversity. He also has a Ph.D. in electrohydrodynamic atomization from Britain's BrunelUniversity. In 1995 he joined AstraZeneca and has worked with its Turbuhaler-brand dry-powder inhalers, pressurized metered dose inhalers (pMDI's) and nebulizers.
His main responsibilities have been electrostatics, fluid dynamics, aerosol science and inhalation technology. He introduced and established Computational Fluid Dynamics as a device development and optimization tool. He has written several publications, and contributed to a number of books and patents. Lastow speaks frequently at conferences and teaches aerosol drug delivery at LundUniversity.